Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines
Status:
Terminated
Trial end date:
2019-01-17
Target enrollment:
Participant gender:
Summary
To evaluate the safety of secondary chemotherapy induced thrombocytopenia (reduction in
platelets which leads to bleeding) prophylaxis with romiplostim in ovarian cancer subjects
receiving myelosuppressive (blood cell damaging) chemotherapy.It is anticipated that
Romiplostim, when administered at an effective dose and schedule, will be a well-tolerated
treatment for subjects experiencing chemotherapy-induced thrombocytopenia.
Phase:
Phase 2
Details
Lead Sponsor:
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH